TOP TEN perturbations for 39721_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39721_at
Selected probe(set): 202711_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39721_at (202711_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 16 (BS-149) / normal astrocyte sample
Relative Expression (log2-ratio):2.7319002Number of Samples:2 / 3
| Experimental | glioma study 16 (BS-149) |
| Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
rapidly progressive glomerulonephritis; ANCA-associated vasculitis study 5 (tubulointerstitium) / focal segmental glomerulosclerosis study 9 (glomerulus)
Relative Expression (log2-ratio):-2.0388508Number of Samples:21 / 10
| Experimental | rapidly progressive glomerulonephritis; ANCA-associated vasculitis study 5 (tubulointerstitium) |
| Tubulointerstitium tissue sample obtained by microdissection from kidney biopsy, from patients suffering from rapidly progressive glomerulonephritis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Donors were positive for ANCA-antibody. Biopsy samples were obtained from the European Renal cDNA Bank-Kroener-Fresenius biopsy bank. All biopsies were stratified by a reference pathologist. | |
| Control | focal segmental glomerulosclerosis study 9 (glomerulus) |
| Glomeruli tissue sample obtained by microdissection from kidney biopsy, from patients suffering from focal segmental glomerulosclerosis. Biopsy samples were obtained from the European Renal cDNA Bank-Kroener-Fresenius biopsy bank. All biopsies were stratified by a reference pathologist. |
bisacodyl study 4 (3975ng/ml) / vehicle (DME) treated bronchial epithelial cell sample
Relative Expression (log2-ratio):-1.6891832Number of Samples:3 / 17
| Experimental | bisacodyl study 4 (3975ng/ml) |
| Bronchial epithelial cells (NHBE) treated with bisacodyl (3975ng/ml; vendor: Prestwick Chemical / catalog number: 419 / catalog name: Bisacodyl [603-50-9]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:, , | |
| Control | vehicle (DME) treated bronchial epithelial cell sample |
| Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). |
gefitinib study 2 / wild type A431 cell sample
Relative Expression (log2-ratio):-1.6158638Number of Samples:3 / 3
| Experimental | gefitinib study 2 |
| Gefitinib-resistant A431 (A431 GR) cells generated by growing parental cells in the presence of increasing concentrations of gefitinib up to 3 μM. Cells were selected and maintained in gefitinib (3μM). ATC code: | |
| Control | wild type A431 cell sample |
| A431 wild type cells. |
stem cell differentiation study 41 (T3pi) / undifferentiated hES-T3 cell sample
Relative Expression (log2-ratio):1.5914536Number of Samples:2 / 3
| Experimental | stem cell differentiation study 41 (T3pi) |
| Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype. | |
| Control | undifferentiated hES-T3 cell sample |
| Undifferentiated human embryonic stem cells T3. |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):1.5859966Number of Samples:20 / 19
| Experimental | atopic dermatitis study 12 (non-lesional; adults) |
| Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (non-lesional; children) |
| Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)
Relative Expression (log2-ratio):1.5548964Number of Samples:20 / 18
| Experimental | atopic dermatitis study 12 (lesional; adults) |
| Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (lesional; children) |
| Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
precursor-B-ALL study 3 (hyperdiploid) / T-ALL study 3
Relative Expression (log2-ratio):1.5065174Number of Samples:17 / 29
| Experimental | precursor-B-ALL study 3 (hyperdiploid) |
| Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
| Control | T-ALL study 3 |
| Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)
Relative Expression (log2-ratio):-1.4606113Number of Samples:3 / 2
| Experimental | prostate cancer study 8 (p. canc) |
| CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | prostate cancer study 8 (ptasc) |
| CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):-1.4126797Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |